UNSPSC 51181608: Levothyroxine or thyroxine or triiodothyronine

This classification denotes a generic primary tumor tnm finding with the molecular formula C15H11I4NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q51BO43MG4, chemically known as 3,5,3,5-tetraiodothyronine but generally known as levothyroxine, which bears US NIH Compound Identifier 853. European Medicines Agency schedules Levothyroxine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02917MIG. SMILES: C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)O)N.

UNSPSC 51181608 Levothyroxine or thyroxine or triiodothyronine is a Commodity code under which state and local governments procure thyroid-replacement pharmaceuticals as part of broader generic multi-source drug formularies and OTC product agreements. The scope covers branded and generic formulations of levothyroxine, triiodothyronine, and related thyroid medications supplied through authorized pharmaceutical wholesalers to state agencies, county health systems, and other public health facilities. Issuing bodies include state health and human services departments and multistate cooperative purchasing alliances that aggregate demand across member jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents a significant buyer under this code, using cooperative purchasing to standardize pricing and supply chains across participating states.

The code shows recent activity concentrated in the Upper Midwest and Pacific Northwest, with MMCAP's January 2026 RFP explicitly covering Minnesota and Oregon participants. On January 20, 2026, MMCAP issued Request for Proposal S1070000015802 for Generic Multi Source Pharmaceuticals and OTC Products, seeking manufacturers to supply comprehensive product lines including levothyroxine formulations through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. The RFP requires vendors to submit detailed product information by National Drug Code (NDC), maintain compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), hold contractual relationships with at least two of the three authorized wholesalers, and offer pricing flexibility through formats including flat price, net price, or WAC-minus structures. Proposals were due March 26, 2026, with awarded contracts effective July 1, 2026 for a two-year initial term. Vendors must maintain commercial general liability insurance of $5 million per occurrence, network security and privacy liability of $2 million, and professional liability of $2 million, and accept a 3 percent administrative fee on all contract purchases with performance penalties ranging from $200 to $1,500 per violation.